Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors - Wikidata - awgldk - TriplyDB

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

http://www.wikidata.org/entity/Q28086999

about

Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation Viral cancer therapies: are they ready for combination with other immunotherapies?Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model.Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.

P2860

Q33566511-A70D67EC-885C-4AE9-A683-4194E9D51A64 Q38647011-D317C2E6-EEE6-4E4C-9DED-0E8BF14E1396 Q40192795-60B3FE6A-B1B7-461A-BAB2-82445B957091 Q40287020-9905BED2-AF06-4B21-AFA3-23AE310322B3 Q42373489-0F6F30DF-FB4C-47AD-B1EE-8E50B02437BE Q50053595-DD423642-BC00-46B3-BC9C-E9EDB209776A Q54221621-DCF8172D-48C2-441F-BC84-7D97E5186FDA

P2860

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

http://www.wikidata.org/entity/Q28086999

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@ast

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@en

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@nl

type

label

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@ast

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@en

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@nl

prefLabel

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@ast

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@en

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@nl

P1433

Q28086999-D8CDAAC6-AC7B-4D17-8676-46E528EB2274

P1476

Q28086999-05E2209A-CDF4-4223-816D-0897E3419BB3

P2093

Q28086999-C5E7B8DA-1C02-46CD-85EC-068912A5E8A4

Q28086999-CF5CAAB6-FB33-4DDE-A328-5DB86052D904

P275

Q28086999-2169438A-10F5-49DF-A7EA-65DE459D78F3

P2860

Q28086999-01FFC032-6B6A-49DD-BD8E-BA351F6964A2

Q28086999-02B073FD-8F41-44E6-A780-4243512857A9

Q28086999-041FBB32-09E0-4716-A69C-B1142C879B5D

Q28086999-0480D328-1CD6-4885-95CE-038682ECD7A4

Q28086999-04B0D4F3-A674-4AF0-B8C8-9DC96AD695F0

Q28086999-0680D878-A0AB-4C71-AA41-22D710619F0E

Q28086999-06943CF5-76DF-4E49-85E7-FB870F9C3528

Q28086999-0724A35D-4D10-4EE0-9FE0-41A38B0BBE46

Q28086999-0C63C640-5E5B-4E06-99B2-9F10BA56278F

Q28086999-16614EFF-D3FD-4BBC-9B3D-43304E49F8E6

P304

Q28086999-95DD1EA9-2D15-4EDA-9352-5CD5EAAF2CB8

P31

Q28086999-27BD51B2-FF83-4C4C-A4FE-2342EDD339EF

Q28086999-B1D9F193-768C-429B-9D22-008365757199

P356

Q28086999-EDC743BB-E329-40CA-AB8B-CA0E1C8844CB

P407

Q28086999-18162286-A833-4231-99E9-5F97547758F9

P433

Q28086999-0BE19BF2-D8F3-4297-9DE9-C220E43886D5

P478

Q28086999-08A6D266-165C-422A-86E2-D38D5D9C7E27

P5008

Q28086999-455F5242-62A4-487D-81C6-8BD071B0FFA5

P577

Q28086999-55BAEF84-F230-4018-8927-866876AE4CB6

P5875

Q28086999-ACDD1739-2D13-437B-AE3E-36BF83CA9E8C

P698

Q28086999-1F028890-2EFF-49F8-A612-7FCE4ADD0391

P921

Q28086999-9D11ECEC-C80A-4C71-AA35-1D425FA24605

Q28086999-9D444FB5-57F5-4BB7-A952-C87C68EC809B

Q28086999-D3A6C6FC-3EFA-42F3-8D62-4BB6E06EB1A1

P932

Q28086999-0F872338-326E-4C43-A33A-6932534FE2FA

P356

P1433

P1476

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

@en

P2093

Karishma Rajani

http://www.w3.org/2001/XMLSchema#string

Richard Vile

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Hallmarks of Cancer: The Next Generation

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The PD-1 pathway in tolerance and autoimmunity

Cancer immunoediting from immune surveillance to immune escape

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Nivolumab plus ipilimumab in advanced melanoma.

P304

5889-901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/V7112914

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284170897

http://www.w3.org/2001/XMLSchema#string

P698

26580645

http://www.w3.org/2001/XMLSchema#string

P921

P932

4664987

http://www.w3.org/2001/XMLSchema#string